Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
The failure of two other beta amyloid targeting agents this year – AC Immune and Roche’s crenezumab and Eisai and Biogen’s aducanumab has lead many to declare the need to ... The loss of CNP520 leaves just one major BACE inhibitor standing –
Latest news
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
Also eyecatching were Woodcock’s comments on two high profile FDA approvals of spinal muscular atrophy (SMA) treatments, Biogen’s Spinraza and Novartis’ gene therapy Zolgensma.
-
EMD Serono allies with ‘free sequencing’ firm Nebula
This approach is already being used in the UK Biobank project – backed by a consortium of pharma and biotech companies including Regeneron, AbbVie, Alnylam, AstraZeneca, Biogen, and Pfizer – with data now
-
Syncona start-up Quell Therapeutics appoints chief exec
One investment in the field has just paid off, with gene therapy company Nightstar being sold to Biogen for $800m..
-
Biogen trumpets safety data for Tecfidera follow-up
Much riding on blockbuster's successor. As the FDA continues its review of Biogen’s follow-up to multiple sclerosis blockbuster Tecfidera, the company has reported new data making a case ... Alkermes-partnered diroximel fumarate (formerly BIIB098) –
-
AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy
mechanism to the long list of amyloid- and tau-targeting drugs that have so far comprehensively failed to show any significant benefit in neurodegenerative disorders, including most recently Biogen’s aducanumab.
More from news
Approximately 105 fully matching, plus 281 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Nightstar was bought by Biogen for $800m in March.
-
#OrkambiNow?
But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and
-
Where next in Alzheimer’s disease R&D?
Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab
-
Drug launches to watch in 2019
only other SMA treatment available, Biogen’s Spinraza.
-
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
However, research from RAND and the University of Southern California that was sponsored by Biogen has found that several European countries lack the capacity to rapidly move a disease-modifying treatment
More from intelligence
Approximately 1 fully matching, plus 38 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Healthcircle
Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.
-
Attigo (part of the Mednet Group)
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
IGNIFI
Allergan . Biogen . Boehringer Ingelheim . Danone Nutricia . Ferring Pharmaceuticals . MSD Healthcare Services .
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
-
Bedrock Healthcare Communications
Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
Featured jobs
- Publications Director, Medical Communications agency, Cambridge
-
Competitive Salary
- Publications Director, Medical Communications agency, Oxford
-
Competitive Salary
- Strategic Associate Director Healthcare PR, London
-
Substantiel package
- Publications Director, Medical Communications agency, Home Based...
-
Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
- Client Partner, Healthcare Brand Communications, London
-
Highly competitive package
Subscribe to our email news alerts
- Von der Leyen elected new European Commission president
- Novartis raises 2019 guidance as new products gather speed
- New digital director for 90TEN
- Elon Musk’s NeuraLink applies to trial ‘brain-machine interface’
- New UK leadership roles at WPP Health Practice
- We are Gold! Porterhouse Medical Group is recognised as an ‘Investor in People’ at the Gold level
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Precision paediatrics: Treating patients with CAR-T
- Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
- What does it mean to be an agile organisation
- We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
- Battling breast cancer with precision medicine (Part 2)
- Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...
Quick links
Infographics
